A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Connor Frey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. Hauptthemen laut MEDLINE: Carbapenems, Pharmacovigilance, Anti-Bacterial Agents, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Carbapenem antibiotics are critical therapies for multidrug-resistant infections, but their comparative haematologic safety profiles remain poorly characterized. We systematically evaluated haematologic adverse events associated with meropenem, ertapenem, imipenem and doripenem using pharmacovigilance data.
Methods
We analyzed the FDA Adverse Event Reporting System (FAERS) database from January 2013 to July 2025. Disproportionality analysis was performed using reporting odds ratios (RORs) with 95% confidence intervals for haematologic adverse events.
Results
Sixteen distinct haematologic adverse events were identified. Meropenem demonstrated the most extensive toxicity profile with significant signals for 15 adverse events, including severe conditions: thrombocytosis (ROR = 24.941), eosinophilia (ROR = 24.663), bone marrow failure (ROR = 13.113), agranulocytosis (ROR = 11.57) and pancytopenia (ROR = 11.131). Imipenem demonstrated signals for nine events, notably thrombocytopenia and eosinophilia. Ertapenem demonstrated nine events: leucopenia (ROR = 3.843) and neutropenia (ROR = 2.469). No reports were identified for doripenem.
Conclusions
Significant differences exist in haematologic safety profiles among carbapenems. Meropenem shows the broadest spectrum of severe toxicity, while other carbapenems demonstrate fewer reports. demonstrates fewer reported haematologic safety signals and not a most favourable haematologic safety profile. These differential safety profiles should inform further studies on carbapenem selection, including patients with baseline haematologic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada.
ORCID-Profile: Connor Frey, Parham Elmi
Zitieren
APA
Frey, C., & Elmi, P. (2026). A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag060
Vancouver
Frey C, Elmi P. A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag060
BibTeX
@article{Frey2026,
author = {Frey, Connor and Elmi, Parham},
title = {A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag060}
}
EUVIMED